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Pulmonary embolism
- the great masquerader

Pulmonary embolism (PE)
is a blockage of the main
artery of the lung or one of its
branches by a substance that
has travelled from elsewhere
in the body through the
bloodstream (embolism). PE
most commonly results from
deep vein thrombosis (a blood
clot in the deep veins of the
legs or pelvis) that breaks off
and migrates to the lung, a
process termed venous
thromboembolism (VTE).
http://emedicine.medscape.com/article/300901-overview

CLASSIFICATION OF  PULMONARY EMBOLISM
• Massive  PE  
accounts  for  5-10%  of cases
• Submassive PE 
accounts for  20-25% of  patients
• Low-risk 
constitutes about 70-75% of  cases
• dyspnea，
• syncope，
• hypotension，
• cyanosis
• RV  dysfunction (right  heart  failure) 
despite 
• normal  systemic  arterial  pressure.
CLASSIFICATION OF  PULMONARY EMBOLISM
Acute
situated centrally within the
vascular lumen or if it
occludes a vessel (vessel cut
- off sign)
Chronic
it is eccentric and contiguous
with the vessel wall, it
reduces the arterial diameter
by more than 50%, evidence
of recanalization within the
thrombus is present, and an
arterial web is present.
Central
main pulmonary artery, the left
and right main pulmonary
arteries, the anterior trunk, the
right and left interlobar
arteries, the left upper lobe
trunk, the right middle lobe
artery, and the right and left
lower lobe arteries
Peripheral
segmental and
subsegmental arteries of
the right upper lobe, the
right middle lobe, the
right lower lobe, the left
upper lobe, the lingula,
and the left lower lobe
http://emedicine.medscape.com/article/300901-overview
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-
Management-of

Predisposing factors of
PULMONARY EMBOLISM Venous stasis
 Hypercoagulable states
 Immobilization
 Surgery and trauma
 Pregnancy
 Oral contraceptives and estrogen replacement
 Malignancy
 Warfarin (first few days of therapy)
 Central venous instrumentation - past 3 months
 Hereditary factors (Protein C deficiency, factor V Leiden, plasminogen
activator abnormality etc.)
 Acute medical illness (AIDS (lupus anticoagulant), Behçet disease,
myocardial infarction, systemic lupus erythematosus, polycythemia, ulcerative colitis
etc.)
http://emedicine.medscape.com/article/300901-overview
Virchow
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of

http://reference.medscape.com/features/slideshow/pulmonary-embolism?src=wnl_ref_clinfo&uac=200127DN&impID=886985&faf=1#page=14
ESC Guidelines 2014
PULMONARY EMBOLISM: Pathophysiology
N          thrombus       embolus
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: clinical picture
 Abrupt onset of pleuritic chest pain
 Shortness of breath
 Hypoxia
 Seizures
 Syncope
 Abdominal pain
 Fever
 Productive cough
 Wheezing
 Decreasing level of consciousness
 New onset of atrial fibrillation
 Hemoptysis
 Flank pain
• Delirium (in elderly patients)
ESC Guidelines 2014
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: Physical Examination
Physical signs:
• Tachypnea (RR>16/min) - 96%
• Rales - 58%
• Accentuated second heart sound - 53%
• Tachycardia (heart rate >100/min) - 44%
• Fever (temperature >37.8°C) - 43%
• Diaphoresis - 36%
• S 3 or S 4 gallop - 34%
• Clinical signs and symptoms of thrombophlebitis - 32%
• Lower extremity edema - 24%
• Cardiac murmur - 23%
• Cyanosis - 19%
http://emedicine.medscape.com/article/300901-overview
PULMONARY EMBOLISM: Physical Examination
may be grouped into 4 categories as follows:
 Massive pulmonary infarction
 Acute pulmonary infarction
 Acute embolism without infarction
 Multiple pulmonary emboli or thrombi
http://emedicine.medscape.com/article/300901-overview
PULMONARY EMBOLISM: massive
thrombus
thrombus
thrombus
heart
heart
PULMONARY EMBOLISM: acute pulmonary 
infarction
Lung infarctionthrombus
PULMONARY EMBOLISM: acute embolism without 
infarction
PULMONARY EMBOLISM: multiple pulmonary emboli or 
thrombi
These two coronal CT
images are of the same
patient who presented with
dyspnea, chest pain, and
mild core pulmonale. The
chest CT angiogram reveals
multiple PE (arrows) as was
suspected by clinical
observations. Pulmonary
emboli were found in
several secondary, tertiary,
and distal branches of the
pulmonary arteries.
PULMONARY EMBOLISM: Assessment of clinical probability
American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP)
(Canadian Pulmonary Embolism Score)
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: D-dimer testing
• D-dimer testing is most reliable for excluding
pulmonary embolism in younger patients who have no
associated comorbidity or history of venous
thromboembolism and whose symptoms are of short
duration
• it is of questionable value in patients who are older
than 80 years, who are hospitalized, who have cancer,
or who are pregnant, because nonspecific elevation of
D-dimer concentrations is common in such patients
• D-dimer testing should not be used
when the clinical probability of
pulmonary embolism is high
http://emedicine.medscape.com/article/300901-overview
Potentially useful laboratory tests in 
patients with suspected pulmonary 
embolism include: 
 D-dimer testing
 Ischemia-modified albumin level
 White blood cell count
 Arterial blood gases
 Markers of myocardial injury - serum troponin and liptin
levels
 Markers of right ventricular dysfunction - brain natriuretic
peptide
http://emedicine.medscape.com/article/300901-overview
Laboratory tests and biomarkers
Markers of right ventricular dysfunction
In normotensive patients with PE, the positive predictive value of elevated BNP or NT-proBNP concentrations
for early mortality is low. Haemodynamically stable patients with low NT-proBNP levels may be candidates for
early discharge and outpatient treatment
Markers of myocardial injury
Elevated plasma troponin concentrations on admission have been reported in connection with PE and were
associated with worse prognosis (troponin T concentrations >14 pg/mL).
Elevated serum creatinine levels and a decreased (calculated) glomerular filtration rate are related to 30-day all-
cause mortality in acute PE.
Imaging studies that aid in the
diagnosis of pulmonary embolism
PULMONARY EMBOLISM: computed 
tomographic pulmonary angiography
is the initial imaging modality of choice for stable patients with suspected pulmonary embolism.
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: Lung scintigraphy
with multiple tracers such as xenon-133 gas, Tc-99m-labelled aerosols, or Tc-99m-labelled carbon microparticles
(Technegas)
The high-probability criteria are as follows:
 Two large (>75% of a segment) segmental perfusion defects
without corresponding ventilation or chest radiographic
abnormalities
 One large segmental perfusion defect and 2 moderate (25-75%
of a segment) segmental perfusion defects without
corresponding ventilation or radiographic abnormalities
 Four moderate segmental perfusion defects without
corresponding ventilation or chest radiographic abnormalities
 The intermediate-probability criteria are as follows:
 One moderate to fewer than 2 large segmental perfusion defects
without corresponding ventilation or chest radiographic
abnormalities
 Corresponding V/Q defects and radiographic parenchymal
opacity in lower lung zone
 Single moderate matched V/Q defects with normal chest
radiographic findings
 Corresponding V/Q and chest radiography small pleural
effusion
 Difficult to categorize as normal, low, or high probability
http://emedicine.medscape.com/article/300901-overview
http://reference.medscape.com/features/slideshow/pulmonary-embolism?src=wnl_ref_clinfo&uac=200127DN&impID=886985&faf=1#page=21
PULMONARY EMBOLISM: pulmonary 
angiography
This angiograph is a localization image that shows
placement of the pigtail catheter in the pulmonary
artery for selective angiography. The radiograph on
the left is the positive image and on the right the
negative image.
On the right is a magnified portion of the radiograph showing a large
filling defect in a branch of the pulmonary artery, which is a
pulmonary embolus (arrows). This patient presented with ah clinical
history of chest pain, advanced peripheral vascular disease, diabetic,
smoker, and hypertension.
PULMONARY EMBOLISM: magnetic resonance angiography
Magnetic resonance angiography is performed following intravenous administration of gadolinium. 
Emboli in the left and right main 
pulmonary arteries
Embolus in the left main 
pulmonary artery
А large pulmonary embolus in the left 
main branch of the pulmonary artery
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: X-
ray
thrombus
Hampton humpPalla’s sign
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: Echocardiography
on depressed contractility of the RV free 
wall compared with the RV apex
PULMONARY EMBOLISM: compression venous 
ultrasonography
two crossection ultrasound images through the right common femoral
vein (CFV) show a large nonocclusive thrombus in the vessel lumen
(yellow arrow). The image on the left shows the common femoral
vein prior to compression being applied with a large clot within it
ession
PULMONARY EMBOLISM: ECG
inversion of T waves
in leads V1 – V4
S1Q3T3 pattern
QR pattern in V1
Q
R
50 MM/S 
Uncompleted RBBB
(McGinn-White sign)
PULMONARY EMBOLISM: differential 
diagnoses 
 Musculoskeletal pain
 Pleuritis
 Pericarditis
 Salicylate intoxication
 Hyperventilation
 Silicone pulmonary embolism
 Lung trauma
 Mediastinitis, acute
• Sickle cell disease
http://emedicine.medscape.com/article/300901-overview
ESC Guidelines, 2014
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
ESC Guidelines, 2014
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of
PULMONARY EMBOLISM: 
Treatment in the acute phase
• Haemodynamic and respiratory support
• Anticoagulation
• Thrombolytic treatment
• Surgical embolectomy
• Percutaneous catheter-directed treatment
• Venous filters
• Early discharge and home treatment
http://emedicine.medscape.com/article/300901-overview
Haemodynamic and respiratory support
Acute RV failure with resulting low systemic output is the leading cause of death in patients with 
high-risk PE.
• Use of vasopressors is often necessary, in parallel with (or while waiting for) pharmacological,
surgical, or interventional reperfusion treatment. Norepinephrine appears to improve RV function via
a direct positive inotropic effect, while also improving RV coronary perfusion by peripheral vascular
alpha-receptor stimulation and the increase in systemic BP.
• Vasodilators decrease pulmonary arterial pressure and pulmonary vascular resistance, but the main
concern is the lack of specificity of these drugs for the pulmonary vasculature after systemic
(intravenous) administration.
• Hypoxaemia is usually reversed with administration of oxygen. When mechanical ventilation is
required, care should be taken to limit its adverse haemodynamic effects. In particular, the positive
intrathoracic pressure induced by mechanical ventilation may reduce venous return and worsen RV
failure in patients with massive PE. Low tidal volumes (approximately 6 mL/kg lean body weight)
should be used in an attempt to keep the end-inspiratory plateau pressure <30 cm H2O.
Anticoagulation
In patients with acute PE, anticoagulation is recommended, with the objective of preventing both early death and recurrent 
symptomatic or fatal VTE. The standard duration of anticoagulation should cover at least 3 months.
Anticoagulation medications include the following:
• Unfractionated heparin
• Low-molecular-weight heparin
• Factor Xa Inhibitors
• Fondaparinux
• Warfarin
Thrombolytic agents used in managing pulmonary embolism 
include the following:
• Alteplase
• Reteplase
• Urokinase
• Streptokinase
Diagnostic investigations should not delay empirical anticoagulant therapy. Thrombolytic therapy should
be used in patients with acute pulmonary embolism who have hypotension (systolic blood pressure< 90 mm
Hg) who do not have a high bleeding risk and in selected patients with acute pulmonary embolism not
associated with hypotension who have a low bleeding risk and whose initial clinical presentation or clinical
course suggests a high risk of developing hypotension. Long-term anticoagulation is critical to the
prevention of recurrence of DVT or pulmonary embolism, because even in patients who are fully
anticoagulated, DVT and pulmonary embolism can and often do recur.
http://reference.medscape.com/features/slideshow/pulmonary-embolism?src=wnl_ref_clinfo&uac=200127DN&impID=886985&faf=1#page=4
The first is systemic thrombolysis followed by anticoagulation (shock). The second is catheter-directed thrombolysis.  
• Thrombolytic therapy should be used in patients
with acute PE associated with hypotension
(systolic BP < 90 mm HG), who do not have a
high bleeding risk
• Thrombolytic therapy is suggested in select
patients with acute PE not associated with
hypotension and with a low bleeding risk whose
initial clinical presentation or clinical course
after starting anticoagulation suggests a high
risk of developing hypotension
• Assessment of PE severity, prognosis, and risk
of bleeding dictate whether thrombolytic therapy
should be started. Thrombolytic therapy is not
recommended for most patients with acute PE
not associated with hypotension
Thrombolytics
Thrombolysis is indicated for hemodynamically unstable patients with pulmonary embolism.
Thrombolysis dramatically improves acute cor pulmonale. Thrombolytic therapy has replaced surgical
embolectomy as the treatment for hemodynamically unstable patients with massive pulmonary embolism.
Fibrinolytic regimens currently in common use for pulmonary embolism include 2 forms of recombinant
tPA, alteplase and reteplase, along with urokinase and streptokinase.
Alteplase usually is given as a front-loaded infusion over 90
or 120 minutes.
Urokinase and streptokinase usually are given as infusions
over 24 hours or more.
Reteplase is a new-generation thrombolytic with a longer
half-life; it is given as a single bolus or as 2 boluses
administered 30 minutes apart.
Reteplase and alteplase are preferred for patients with
pulmonary embolism
Streptokinase is least desirable of all the fibrinolytic agents
because antigenic problems and other adverse reactions
Percutaneous catheter-directed treatment
For patients with absolute
contraindications to thrombolysis,
interventional options include:
(i) thrombus fragmentation with pigtail or
balloon catheter,
(ii) rheolytic thrombectomy with
hydrodynamic catheter devices,
(iii) suction thrombectomy with aspiration
catheters and
(iv) rotational thrombectomy.
On the other hand, for patients without
absolute contraindications to thrombolysis,
catheter-directed thrombolysis or
pharmacomechanical thrombolysis are
preferred approaches.
Catheter-directed, Ultrasound-facilitated thrombolysis

Surgical embolectomy
The first successful surgical pulmonary embolectomy was performed in 1924, 
several decades before the introduction of medical treatment for PE.
Following rapid transfer to the operating room and induction of anaesthesia
and median sternotomy, normothermic cardiopulmonary bypass should be
instituted.
Aortic cross-clamping and cardioplegic cardiac arrest should be avoided.
With bilateral PA incisions, clots can be removed from both pulmonary
arteries down to the segmental level under direct vision.
Prolonged periods of post-operative cardiopulmonary bypass and weaning
may be necessary for recovery of RV function.
Parenteral anticoagulation
In patients with high or intermediate clinical
probability for PE, parenteral anticoagulation
should be initiated whilst awaiting the results of
diagnostic tests. Immediate anticoagulation can
be achieved with parenteral anticoagulants such
as intravenous UFH, subcutaneous low-
molecular-weight heparin (LMWH),or
subcutaneous fondaparinux. UFH is
recommended for patients in whom primary
reperfusion is considered, as well as for those
with serious renal impairment (creatinine
clearance < 30 mL/min), or severe obesity.
LMWH or fondaparinux are preferred over UFH
for initial anticoagulation in PE.
http://www.medscape.com/viewarticle/715597_2?sa=X&ved=0CB0Q9QEwBGoVChMI5u_X-s3zxgIVBV0sCh2HGQZD
Heparin major anticoagulant
effect by inactivating thrombin
and activated factor X (factor Xa)
through an antithrombin (AT)-
dependent mechanism. Heparin
binds to AT through a high-
affinity pentasaccharide, which is
present on about a third of
heparin molecules. For inhibition
of thrombin, heparin must bind to
both the coagulation enzyme and
AT, whereas binding to the
enzyme is not required for
inhibition of factor Xa.
Heparin action
Unfractionated heparin infusion
should be stopped during
administration of streptokinase or
urokinase
Available oral anticoagulants include:
• vitamin K antagonists (warfarin),
• direct thrombin inhibitors (dabigatran), 
• direct factor Xa inhibitors (rivaroxaban)
(The image shows red blood cells
enmeshed in a fibrinous matrix in the
process of clot formation.)
Oral anticoagulants should be initiated as soon as possible, and
preferably on the same day as the parenteral anticoagulant.
VKAs have been the ‘gold standard’ in oral anticoagulation for
more than 50 years.
vitamin K antagonists (warfarin)
https://sciphu.files.wordpress.com/2008/11/vitamin-k-cycle.jpg
The anticoagulant effect of warfarin is mediated by the inhibition of vitamin K–dependent factors, which are II,
VII, IX, and X. The peak effect does not occur until 36-72 hours after drug administration, and the dosage is
difficult to titrate. A prothrombin time ratio is expressed as an INR and is monitored to assess the adequacy of
warfarin therapy. The recommended therapeutic range for venous thromboembolism is an INR of 2-3. This level
of anticoagulation markedly reduces the risk of bleeding without the loss of effectiveness.
Warfarin can be started at a dose of 10 mg
in younger (e.g. ,60 years of age),
otherwise healthy outpatients, and at a
dose of 5 mg in older patients and in those
who are hospitalized. The daily dose is
adjusted according to the INR over the
next 5–7 days, aiming for an INR level of
2.0–3.0.
Direct thrombin inhibitors (dabigatran)
Dabigatran etexilate is a competitive reversible non-peptide antagonist of thrombin. Thrombin is a
multifunctional enzyme which converts fibrinogen to fibrin, cross-linking fibrin monomers via
activation of factor XIII and augmenting further thrombin production via the activation of factors V and
VIII. It also activates platelets, generates anticoagulant activity via activation of protein C and initiates
numerous cellular processes including wound healing.
Indicated for treatment of deep vein thrombosis (DVT)
and pulmonary embolus (PE) in patients who have been
treated with a parenteral anticoagulant for 5-10 days
Also indicated to reduce the risk of recurrence of DVT
and PE in patients who have been previously treated
• CrCl >30 mL/min: 150 mg PO BID
• CrCl ≤30 mL/min or on dialysis: Dosage
recommendations cannot be provided
• CrCl <50 mL/min with concomitant use of P-gp
inhibitors: Avoid co-administration
Direct factor Xa inhibitors (rivaroxaban)
Rivaroxaban is a competitive reversible antagonist of activated factor X (Xa). Factor Xa is the active
component of the prothrombinase complex that catalyses conversion of prothrombin (factor II) to
thrombin (factor IIa).
CONTRAINDICATIONS: 
• Active pathological bleeding 
• Severe hypersensitivity reaction
http://reference.medscape.com/features/slideshow/pulmonary-embolism?src=wnl_ref_clinfo&uac=200127DN&impID=886985&faf=1#page=4


Vena Cava Filters
The current grade 1B recommendation is that patients with acute PE should not routinely receive vena cava filters in
addition to anticoagulants. An ideal IVC filter should be easily and safely placed using a percutaneous technique,
biocompatible and mechanically stable, and able to trap emboli without causing occlusion of the vena cava
• Patients with acute venous thromboembolism
who have an absolute contraindication to
anticoagulant therapy (eg, recent surgery,
hemorrhagic stroke, significant active or recent
bleeding)
• Patients with massive PE who survived but in
whom recurrent embolism invariably will be fatal
• Patients who have objectively documented
recurrent venous thromboembolism, adequate
anticoagulant therapy notwithstanding
INDICATED FOR:
Supportive Care
Compression stockings
For patients who have had a
proximal DVT, the use of
elastic compression stockings
provides a safe and effective
adjunctive treatment that can
limit postphlebitic syndrome.
Stockings with a pressure of
30-40 mm Hg at the ankle,
worn for 2 years following
diagnosis, are recommended
(grade 2B) to reduce the risk
of postphlebitic syndrome.
Additional support therapies
100%
30-40%
• Dopamine and dobutamine are the usual
inotropic agents.
• Mechanical ventilation may be necessary to
provide respiratory support and as adjunctive
therapy for a failing circulatory system.
• Transfusion with packed red blood cells
(either simple or exchange) improves
oxygenation immediately.
• IV fluids may help or may hurt the patient
who is hypotensive.
Pulmonary Embolism in Pregnancy
The risk of venous thromboembolism is increased during pregnancy and the postpartum period.
Pulmonary embolism is the leading cause of death in pregnancy. DVT and pulmonary embolism are
common during all trimesters of pregnancy and for 6-12 weeks after delivery.
• The diagnostic approach to patients with pulmonary embolism should be exactly
the same in a pregnant patient as in a nonpregnant one.
• A nuclear perfusion lung scan is safe in pregnancy, as is a chest CT scan.
• If the patient has a low pretest probability for pulmonary embolism and a normal
D-dimer test result, clinical exclusion from further investigations is recommended.
• When the suspicion is high, the patients should have bilateral leg Doppler
assessment.
• If the results are negative, CT pulmonary angiography is the next step.
• Heparin and fibrinolysis are safe in pregnancy. Warfarin is contraindicated,
because it crosses the placental barrier.
• Therapeutic treatment with unfractionated heparin or LMWH during pregnancy,
with anticoagulation continuing for 4-6 weeks postpartum and for a total of at least
6 months.
• Pregnant women who are in a hypercoagulable state or who have had previous venous
thromboembolism -prophylactic anticoagulation during pregnancy.
Complications of PE
• Sudden cardiac death
• Obstructive shock
• Pulseless electrical activity
• Atrial or ventricular arrhythmias
• Secondary pulmonary arterial hypertension
• Cor pulmonale
• Severe hypoxemia
• Right-to-left intracardiac shunt
• Lung infarction
• Pleural effusion
• Paradoxical embolism
• Heparin-induced thrombocytopenia
• Thrombophlebitis
Chronic thromboembolic pulmonary 
hypertension
Chronic thromboembolic pulmonary hypertension has been reported to be a long-term complication of PE, 
with a reported cumulative incidence of 0.1–9.1% within the first two years after a symptomatic PE event
Inadequate anticoagulation, large thrombus mass, residual thrombi, and recurrence of VTE
development of CTEPH
a pulmonary vascular remodelling process modified by infection, inflammation, circulating
and vascular-resident progenitor cells, thyroid hormone replacement, or malignancy
Hypercoagulation, ‘sticky’ red blood cells, high platelet counts, and 
‘uncleavable’ fibrinogen, pulmonary microvascular disease
The diagnosis of CTEPH is based on findings
obtained after at least 3 months of effective
anticoagulation, in order to discriminate this
condition from ‘sub-acute’ PE. These findings are:
† mean pulmonary arterial pressure ≥25 mm Hg,
with pulmonary
arterial wedge pressure ≤15 mm Hg;
† at least one (segmental) perfusion defect detected
by perfusion lung scan, or
pulmonaryarteryobstruction seen by MDCT
angiography or conventional pulmonary
cineangiography.
Pulmonary endarterectomy (PEA) is the treatment
of choice for the disease.
Patients who do not undergo surgery, or suffer from
persistent or residual pulmonary hypertension after
PEA, face a poor prognosis.
Advances in balloon pulmonary angioplasty are
continuing in an attempt to make this technique a
therapeutic alternative for selected patients with
non-operable CTEPH
CLINICAL CASE
In the ECG shown in the slide, what are the findings on leads I and III, and what is their relevance to PE?
http://reference.medscape.com/features/slideshow/pulmonary-embolism?src=wnl_ref_clinfo&uac=200127DN&impID=886985&faf=1#page=4
QR pattern in V1
CT venography reveals the presence of deep vein thrombosis (DVT) in the right leg. The
patient's BP declines again to 89/62 mm Hg, and her heart rate is now 110 beats/min. Her
oxygen saturation is 92%.
DIAGNOSIS?
Acute massive unstable Pulmonary Embolism
(unstable when systolic BP remains below 90 mm Hg for more than 15
minutes or when vasopressors are required)
TREATMENT OPTIONS?
The treatment options for hemodynamically unstable PE consist of 
thrombolysis and thrombectomy.
Thrombectomy was performed

